相关实验视频

Updated: Aug 9, 2026

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

针对肝细胞癌的优化个性化适应性放射治疗的II期研究

Daniel J Herr¹, Chang Wang¹, Mishal Mendiratta-Lala²

¹Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.

Clinical cancer research : an official journal of the American Association for Cancer Research

|July 20, 2023

概括

使用患者特异效用分析优化立体体辐射疗法 (SBRT) 在肝功能受损或无法切除的瘤患者中降低了肝毒性,而不会影响瘤控制.

科学领域:

肝病学肝病学是一种肝病学.
辐射瘤学辐射瘤学
医学物理医学物理

背景情况:

立体体辐射疗法 (SBRT) 是肝脏瘤的治疗选择.
肝功能受损或瘤不适合热切除菌的患者存在独特的治疗挑战.
根据个体患者因素优化SBRT对于平衡疗效和毒性至关重要.

研究的目的:

评估一个个性化的,基于实用性的SBRT剂量优化策略.
评估对局部瘤控制和肝功能的影响 (Child-Pugh得分).
在类似的患者队列中,将结果与传统的SBRT进行比较.

主要方法:

预期的II期临床试验,招募患有Child-Pugh A至B8肝功能的患者.
使用定量效用分析进行个性化SBRT剂量优化.
与使用重叠权重的传统SBRT进行比较.

主要成果:

两年的局部进展率为6.4%.
在6个月内与治疗相关的毒性为21%,类似于肝功能保留的患者的SBRT.
与传统的SBRT相比,重叠权重显示出类似的局部控制和显著降低的毒性.

结论:

一个个性化的,基于实用性的SBRT方法可以保持瘤控制.
这种策略可以减少肝功能受损或不可切除的瘤患者的治疗相关毒性.
这种模式为挑战性肝脏瘤病例提供了一个有希望的方法.

更多相关视频

Evaluation of the Feasibility, Safety, and Accuracy of an Intraoperative High-intensity Focused Ultrasound Device for Treating Liver Metastases

Evaluation of the Feasibility, Safety, and Accuracy of an Intraoperative High-intensity Focused Ultrasound Device for Treating Liver Metastases

Published on: January 9, 2019

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...